Polymorphs of a triester compound and methods of use thereof

Stable crystalline polymorphs of Compound I, including monohydrate and anhydrous forms, address the challenge of pharmacokinetic performance, enhancing therapeutic efficacy and administration options for treating inflammatory-related diseases.

WO2026188020A9PCT designated stage Publication Date: 2026-11-12LIFEMINE THERAPEUTICS INC
-1 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/017881
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-03-06
Filing Date
2026-03-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing biologically active compounds face challenges in achieving stable, efficacious, and safe pharmacokinetic performance for treating inflammatory-related diseases.

Method used

The discovery of stable crystalline polymorphs of Compound I, including anhydrous, hydrate, and solvate forms, such as Form 1 (monohydrate), Form 2 (hemi-THF solvate), and Form 3 (anhydrous), which exhibit excellent thermal stability, bioactivity, and pharmacokinetics.

Benefits of technology

These polymorphs provide improved therapeutic efficacy and pharmacokinetic performance, suitable for oral, transdermal, or subcutaneous administration, offering immediate or extended release of Compound I for treating inflammatory-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026017881_12112026_PF_FP_ABST
    Figure US2026017881_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides crystalline forms of Compound I, (R)-4-((4-((3- bromo-2-hydroxy-4-((1-hydroxy-2-methoxy-6-methyl-4-oxocyclohexa-2,5-diene-1- carbonyl)oxy)-5,6-dimethylbenzoyl)oxy)-2,3,6-trimethylbenzoyl)oxy)-2,3,5,6- tetramethylbenzoic acid, in free acid, hydrate, or solvate forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystalline forms, and methods of using crystalline Compound I in dosage forms for therapeutic effects, including treatment of inflammatory -related disease or disorder.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] POLYMORPHS OF A TRIESTER COMPOUND AND METHODS OF USE THEREOF

[0002] RELATED APPLICATION

[0003] This application claims the benefit of U.S. Provisional Application No. 63 / 767,828, filed on March 6, 2025. The entire teachings of the above application are incorporated herein by reference.

[0004] FIELD OF THE APPLICATION

[0005] This application relates to new cry stalline polymorphs of a biologically active compound that are useful for treating diseases and methods of making such compositions.

[0006] BACKGROUND

[0007] Compound I, (7?)-4-((4-((3-bromo-2-hydroxy-4-(( 1 -hydroxy-2-methoxy-6-methyl-4-oxocyclohexa-2,5-diene-l-carbonyl)oxy)-5,6-dimethylbenzoyl)oxy)-2,3,6-trimethylbenzoyl)oxy)-2,3,5,6-tetramethylbenzoic acid, is a potent inhibitor for treating, inter alia, an inflammatory -related disease or disorder. This compound and its synthesis have been described in the US Patent Application No. 18 / 985,577. the international patent applications PCT / US24 / 60722, and PCT / US24 / 60743. Compound T has the structure of formula (I):

[0008]

[0009] Formula (I).

[0010] To improve pharmacokinetic performance, there remains interest in discovering stable, efficacious and safe polymorphs of this compound.

[0011] SUMMARY OF THE INVENTION

[0012] This application is based on the discovery of a stable solid form of Compound I that is suitable for administering to a subject in need for the treatment of diseases. Applying avariety of screening methods, cry stalline patterns show that 19 different solid forms of Compound I. Form 1 to Form 19, have been produced, including anhydrous, hydrate (e.g., monohydrate, dihydrate, metastable hydrate), solvate (e.g., hemi-solvate, DMA solvate, DMSO solvate, THF solvate). Among them, Form 1 (monohydrate), Form 2 (hemi-THF solvate), and Form 3 (anhydrous) exhibit excellent thermal stability, bioactivity', and pharmacokinetics.

[0013] BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.

[0015] FIG. la. Summary of primary polymorph screening results for solvents 1-12.

[0016] FIG. lb. Summary of primary' poly morph screening results for solvents 13-24.

[0017] FIG. 2. Solid Form Diagram for Compound I from primary polymorph screen. FIG. 3. Solid Form Diagram for competitive slurry experiments.

[0018] FIG. 4. Solid Form Diagram for hydration assessment and secondary polymorph screen

[0019] FIG. 5a. XRPD diffractogram of Form 1.

[0020] FIG. 5b. Simultaneous TGA / DSC thermograms of Compound I, Form 1 from Methanol: Water (80:20% v / v).

[0021] FIG. 6a. XRPD diffractogram of Form 2.

[0022] FIG. 6b. Simultaneous TGA / DSC thermograms of Compound I, Form 2 from DCM. FIG. 6c. Simultaneous TGA / DSC thermograms of Compound I, Form 2 from MEK. FIG. 7a. XRPD diffractogram of Form 3 from temperature cycling in MiBK.

[0023] FIG. 7b. Simultaneous TGA / DSC thermograms of Compound I, Form 3.

[0024] FIG. 8a. XRPD diffractogram of Form 4 from slurry ing in 2-propanol at 50°C.

[0025] FIG. 8b. Simultaneous TGA / DSC thermograms of Compound I, Form 4.

[0026] FIG. 9a. XRPD diffractogram of Form 5 from slurrying in ethyl acetate.

[0027] FIG. 9b. Simultaneous TGA / DSC thermograms of Compound I, Form 5.

[0028] FIG. 10a. XRPD diffractogram of Form 6 from temperature cycling in 1,4-Dioxane.

[0029] FIG. 10b. Simultaneous TGA / DSC thermograms of Compound I, Form 6.

[0030] FIG. I la. XRPD diffractogram of Form 7 from temperature cycling in acetic acid.

[0031] FIG. lib. Simultaneous TGA / DSC thermograms of Compound I, Form 7.

[0032] FIG. 12a. XRPD diffractogram of Form 8 from temperature cycling in dimethyl acetami de.

[0033] FIG. 12b. XRPD analysis of Form 8a from temperature cycling in

[0034] dimethyl acetami de after drying.

[0035] FIG. 12c. XRPD analysis of Form 8b obtained from drying Form 16. Form 16 was obtained from a cooling experiment in dimethylacetamide / water.

[0036] FIG. 12d. Simultaneous TGA / DSC thermograms of Compound I, Form 8.

[0037] FIG. 13a. XRPD diffractogram of Form 9 from temperature cycling in acetonitrile.

[0038] FIG. 13b. Simultaneous TGA / DSC thermograms of Compound I, Form 9.

[0039] FIG. 14a. XRPD diffractogram of Form 10 from temperature cycling in 1,2-Dimethoxy ethane.

[0040] FIG. 14b. XRPD diffractogram of Form 10 from temperature cycling in 1,2-Dimethoxyethane and then drying.

[0041] FIG. 14c. Simultaneous TGA / DSC thermograms of Compound I, Form 10.

[0042] FIG. 15a. XRPD diffractogram of Form 11 from temperature cycling in Dimethylsulphoxide.

[0043] FIG. 15b. Simultaneous TGA / DSC thermograms of Compound I, Form 11.

[0044] FIG. 16a. XRPD diffractogram of Form 12 from heating Form 1.

[0045] FIG. 16b. Simultaneous TGA / DSC thermograms of Compound I, Form 12.

[0046] FIG. 17a. XRPD diffractogram of Form 13 from evaporation from acetone.

[0047] FIG. 17b. Simultaneous TGA / DSC thermograms of Compound I. Form 13.

[0048] FIG. 18. XRPD diffractogram of Form 14 from cooling in ethanol.

[0049] FIG. 19a. XRPD diffractogram of Form 15 from cooling in tetrahydrofuran.

[0050] FIG. 19b. Simultaneous TGA / DSC thermograms of Compound I, Form 15.

[0051] FIG. 20a. XRPD diffractogram of Form 16 from cooling / anti -solvent addition in N.N-Dimethylacetamide / water.

[0052] FIG. 20b. Simultaneous TGA / DSC thermograms of Compound I, Form 16.

[0053] FIG. 21. XRPD diffractogram of Form 17 fromheating Form 9 to 110°C.

[0054] Diffractogram is very similar to Form 9 with small peak changes and shifts upon heating. Possibly, a transient form as Form 9 ultimately converts to Form 7 upon removal of the water / solvent.

[0055] FIG. 22. XRPD diffractogram of Form 18 from heating Form 6 to 200°C.

[0056] FIG. 23a. XRPD diffractogram of Form 19 from slurrying Form 3 in 2-propanol:water(50:50%v / v) at 50°C.

[0057] FIG. 23b. Simultaneous TGA / DSC thermograms of Compound I, Form 19.

[0058] FIG. 24a. The three spectra from top to bottom are Form 3, From 19, and Form 3 converted from Form 19 after drying, respectively. Pattern 19 was dried at 40°C under vacuum for 1 day, and XRPD analysis was carried out on the dried material.

[0059] FIG. 24b. The three spectra from top to bottom are Pattern 3, Pattern 19, and Form 3 after 90% RH storage converted to predominantly Form 19, respectively. Form 3 was stored at 90% RH for 1 day and then removed from storage and analysed by XRPD. The data showed predominantly Form 19 after storage.

[0060] FIG. 24c. The five spectra from top to bottom are Form 3, Form 19, Slurry of Form 3 in water (Form 19), Air drying Form 19 (Form 19 maintained), and Drying Form 19 under vacuum (converted to Form 3).

[0061] FIG. 25a. A PXRD stack plot of example diffractograms for Pattern 1 - Pattern 6.

[0062] FIG. 25b. A PXRD stack plot of example diffractograms for Pattern 7 - Pattern 11.

[0063] FIG. 25c. A PXRD stack plot of example diffractograms for Pattern 12 - Pattern 16.

[0064] FIG. 25d. A PXRD stack plot of example diffractograms for Pattern 16 - Pattern 19.

[0065] FIG. 25e. A PXRD stack plot of example diffractograms for Pattern 1 - Pattern 18.

[0066] FIG. 26a. Single Crystal XRD of Form 2: THF Hemi-solvate. The simulated XRPD based on the single crystal data shows a good match with the Form 2 experimental powder diffraction data showing that the crystal analysed is representative of Form 2 bulk sample.

[0067] FIG. 26b. Single Crystal XRD of Form 2: DCM Hemi-solvate. The simulated XRPD based on the single crystal data shows a good match with the Form 2 experimental powder diffraction data showing that the cry stal analysed is representative of Form 2 bulk sample.

[0068] FIG. 26c. Single Cry stal XRD of Form 2: Acetone Hemi-solvate. The simulated XRPD based on the single crystal data shows a good match with the Form 2 experimentalpowder diffraction data showing that the cry stal analysed is representative of Form 2 bulk sample.

[0069] FIG. 26d. Single Crystal XRD of Form 2: MEK Hemi-solvate. The simulated XRPD based on the single cry stal data shows a good match with the Form 2 experimental powder diffraction data from a sample crystallized from MEK.

[0070] FIG. 26e. Single Crystal XRD of Form 2: Methyl Acetate Hemi-solvate. The simulated XRPD based on the single crystal data shows a good match with Form 2 experimental powder diffraction data from a sample cry stallized from acetone.

[0071] FIG. 27. A comparison of the simulated XRPD data from the DCM, acetone, MEK, methyl acetate and THF hemi-solvates show reasonable matches but with some small shifts / differences above 2O°20. This is consistent with the experimental XRPD data from different solvent systems.

[0072] FIG. 28. XRPD overlay of Form 2 samples from different solvent systems. The diffractograms show consistency across the different solvents in the 3-2O°20 region. Some small differences are present in the 2O-4O°20 region for some of the solvents.

[0073] FIG. 29. Polarized Light Microscopy of Form 1.

[0074] FIG. 30. Polarized Light Microscopy of Form 2.

[0075] FIG. 31. Polarized Light Microscopy of Form 3.

[0076] FIG. 32. Polarized Light Microscopy of Form 4.

[0077] FIG. 33. Polarized Light Microscopy of Form 5.

[0078] FIG. 34. Polarized Light Microscopy of Form 6.

[0079] FIG. 35. Polarized Light Microscopy of Form 7.

[0080] FIG. 36. Polarized Light Microscopy of Form 8.

[0081] FIG. 37. Polarized Light Microscopy of Form 9.

[0082] FIG. 38. Polarized Light Microscopy of Form 10.

[0083] FIG. 39. Polarized Light Microscopy of Form 11.

[0084] FIG. 40. Polarized Light Microscopy of Form 12.

[0085] FIG. 41. Polarized Light Microscopy of Form 13.

[0086] FIG. 42. Polarized Light Microscopy of Form 15.

[0087] FIG. 43. Polarized Light Microscopy of Form 16.

[0088] DETAILED DESCRIPTION

[0089] The present disclosure is based in part on the surprising discovery that crystalline polymorphs of (7?)-4-((4-((3-bromo-2-hydroxy-4-((l -hydroxy-2-methoxy-6-methyl-4-oxocyclohexa-2,5-diene-l-carbonyl)oxy)-5,6-dimethylbenzoyl)oxy)-2,3,6-trimethylbenzoyl)oxy)-2,3,5,6-tetramethylbenzoic acid (Compound I, represented by formula (I) as shown herein) in free acid, hydrate, or solvate forms are suitable for oral, transdermal, subcutaneous, or other forms of administration, and can be formulated to provide immediate or extended release of Compound I upon administration. Crystalline polymorphs of Compound I, dosage forms, and formulations comprising crystalline polymorphs of Compound I are described below. Methods of using the crystalline polymorphs of Compound I for treatment are also disclosed, encompassing use of Compound I for therapeutic effects, including treatment of inflammatory-related disease or disorder.

[0090] Crystalline Polymorphs

[0091] This application presents cry stalline polymorphs of Compound I, in the form of free acids (i.e., anhydrous), hydrates, or solvates. Hydrates include hemi-hydrate, mono-hydrate, di-hydrate, tri-hydrate, and poly-hydrate, preferably, mono-hydrate. Solvates include hemisolvate, mono-solvate, sesqui-solvate, di-solvate, poly-solvate, preferably hemi-solvate. The cry stalline polymorphs are characterized by XRPD and other data provided herein. Properties of each crystalline polymorph are described below.

[0092] Form 1 of Compound I is obtained from multiple single organic solvents and also solvent / water mixtures with low to moderate water activity levels. It has low residual solvent, proximately 1 mole equivalent of water present. In some embodiments, it is a monohydrate. Form 1 can be dehydrated to Form 12 after heating to 160°C. Form 12 rehydrated to Form 1 upon slurrying in water. The XRPD of Form 1 shows the pattern of Pattern 1, and in some embodiments, Pattern 1 is used to represent Form 1. Namely, in some embodiments, the term “Pattern X” is used interchangeably with the term “Form X.” For example, Form 2 is represented by Pattern 2, and Form 11 is represented by Pattern 11.

[0093] The TGA of Form 1 from methanol: water (80:20% v / v) showed 2.1% mass loss (theoretically 0.93 mole equiv. water) between 61 and 139°C likely due to bound water. The simultaneous DSC of Form 1 showed a broad endotherm at onset 83.2 °C (peak 102.0°C) associated with the mass loss in the TGA. A further small endotherm is present at onset 219.1°C (peak 220.2 °C) possibly due to the presence of traces of a second form. A final melting endotherm is present at onset 235.6°C (peak 242.6°C).

[0094] 'H NMR spectrum of Form 1 was observed to be consistent with the reference free acid spectrum. No residual methanol was detected. Polarized light microscopy for Form 1 (from Methanol: Water (95:5% v / v)) showed small aggregated particles with some needle-like particles.

[0095] Table 1 provides the XRPD characteristic peaks of Form 1 (Pattern 1).

[0096] Table 1: XRPD Peak List of Pattern 1

[0097]

[0098] Form 2 of Compound I is obtained from multiple organic solvents, e.g. DCM, THF,

[0099] 2-MeTHF, acetone, MEK. XPRD patterns of Form 2 show consistency in diffractograms across different solvents for 3- 2O°20 region, and small differences in 20-40°26 region forsome solvents. Form 2 contains 0.4-0.5 mole equivalents of each respective solvent. Heating Form 2 to 207°C did not allow for desolvation or effective removal of solvent.

[0100] Form 2 is a hemi-solvate and isostructural from a variety of solvents, including THF hemi-solvate, DCM hemi-solvate, acetone hemi-solvate, MEK hemi-solvate, methyl THF hemi-solvate, or methyl acetate hemi-solvate.

[0101] The TGA of Form 2 from DCM showed the following: A 0.5% mass loss between 26 and 72°C due to unbound solvent / water. A 4.2% mass loss (theoretically 0.41 mole equiv. DCM) corresponding with the melting endotherm. DSC of Form 2 showed the following events: An endotherm is present at onset 223.3 °C (peak 232.8 °C). A shoulder is also present on the endotherm. The overlapping endotherms are likely due to melting and solvent loss.

[0102] 'H NMR of Form 2 showed spectrum to be consistent with the reference free acid spectrum. Approximately 0.44 mole equivalents (4.6 wt.%) DCM present. Polarized light microscopy for Form 2 (from Dichloromethane) showed plate-like particles.

[0103] A Form 2 sample (from acetone) was heated to 160°C and XRPD analysis was carried out after cooling to back to ambient temperature. Form 2 was observed by XRPD after heating to 160°C and cooling.

[0104] A Form 2 sample from THF w as heated to 150°C for 15 minutes. The sample was then analyzed by1H NMR analysis to assess the solvent content. 'H NMR spectroscopy for Form 2 from Tetrahydrofuran after heating the sample to 150°C showed the spectrum to be consistent with the reference free acid spectrum. Approximately 0.49 mole equivalents (4.34 wt.%) THF present. DSC showed overlapping melting and solvent loss endotherms at onset 219.9 °C (peaks 230.3 and 234.4°C).

[0105] The TGA of a Form 2 from MEK showed the following: A 4.3% mass loss (theoretically 0.49 mole equiv. MEK) corresponding with the melting / solvent loss endotherms. DSC showed that an endotherm is present at onset 219.6 °C (peak 228.7 °C). A second overlapping endotherm is also present, peak maximum 232.3 °C.

[0106] 'll NMR spectroscopy for Form 2 from methylethyl ketone showed the spectrum to be consistent with the reference free acid spectrum. Approximately 0.49 mole equivalents (4.34 wt.%) MEK present. 'H NMR spectroscopy for Form 2 from ethyl formate dried at 40°C under vacuum for 1 day and then heated to 100°C under vacuum for a further 2 hoursprior to 'H NMR analysis.XH NMR showed the presence of ca. 0.42 mole equivalents (3.8 wt. %) of ethyl formate.

[0107] Table 2 provides the XRPD characteristic peaks of Form 2 (Pattern 2).

[0108] Table 2: XRPD Peak List of Pattern 2

[0109]

[0110] Form 3 of Compound I is anhydrous (i.e., free acid). Form 3 is obtained for example from MiBK, acetic acid, methyl acetate. It contains low residual solvent and shows no significant mass losses in TGA prior to degradation. Form 3 has the highest melting point and is thermodynamically the most stable anhydrous form discovered among these anhydrous forms of Compound I.

[0111] The TGA of Form 3 from MiBK showed the following: A 0.54% (theoretically 0.04 mole equiv. MiBK) mass loss between 30 and 80°C likely due to residual unbound solvent / water. The simultaneous DSC showed the following: A single melting endotherm at onset 242.8 °C (peak 248.1 °C). Polarized light microscopy for Form 3 from MiBK showed small needle-like particles.

[0112] Table 3 provides the XRPD characteristic peaks of Form 3 (Pattern 3).

[0113] Table 3: XRPD Peak List of Pattern 3

[0114]

[0115] Form 4 of Compound 1 is obtained from multiple alcohol systems, e.g., ethanol, 2-propanol. It can also be obtained from drying Form 14. Form 4 contains solvent and water and is potential hydrate or mixed solvate and hydrate. It exhibits similar diffractogram to Form 1. Form 4 will be dehydrated or desolvated to Form 7 after heating to 180°C.

[0116] The TGA of Form 4 obtained from ethanol showed the following: A 3.8% (theoretically 1.7 mole equiv. Water) mass loss between 65 and 165°C likely due to some bound water. The simultaneous DSC of Form 4 showed the following: A broad endotherm at onset 88.0 °C (peak 110.9°C) associated with the mass loss in the TGA. A final melting endotherm is present at onset 238.3°C (peak 244.4°C).

[0117] Polarized light microscopy for Form 4 from ethanol showed small, aggregated particles with no clear morphology.

[0118] Table 4 provides the XRPD characteristic peaks of Form 4 (Pattern 4).

[0119] Table 4: XRPD Peak List of Pattern 4

[0120]

[0121] Form 5 of Compound I is obtained from ethyl acetate. Some residual solvent and water are present in Form 5 prior to conversion to Form 1 upon drying at 40°C under vacuum. Form 5 will be dehydrated and desolvated to Form 12 after heating to 180°C. Form 5 is an unstable solvate or mixed solvate and hydrate, converted to Form 1 upon extensive drying.

[0122] The TGA of Form 5 showed the following: A 5.9% (theoretically 2.7 mole equiv. water) mass loss between 63 and 141°C likely due to bound solvent / water. The simultaneous DSC of Form 5 showed the following events: A broad endotherm at onset 82.3 °C (peak 98.6°C) associated with the mass loss in the TGA. A final melting endotherm is present at onset 242.6°C (peak 247.7°C).

[0123] Polarized light microscopy for Form 5 obtained from ethyl acetate showed small, aggregated particles with a small needle-like morphology.

[0124] Table 5 provides the XRPD characteristic peaks of Form 5 (Pattern 5).

[0125] Table 5: XRPD Peak List of Pattern 5

[0126]

[0127]

[0128] Form 6 of Compound I is obtained from 1,4-dioxane, 1,4-dioxane / water, tetrahydrofuran / n-heptane, methanol, methanol / water, methyl acetate / n-heptane. It can be obtained at high water activity levels during hydration screens. Low residual solvent is present in Form 6 (approximately 2 mole equivalents water present). Form 6 is dehydrated to Form 18 after heating to 200°C. Form 6 is believed to be a dihydrate.

[0129] The TGA of Form 6 from 1,4-Dioxane showed the following: two mass losses of 2.5% and 1.2% between 30 and 139° C likely due to both unbound and bound solvent / water. The simultaneous DSC showed the following: Endotherms associated with the TGA mass losses at onset 48.9°C (peak 83.6°C) and onset 106.8°C (122.4°C). A small endotherm is present at onset 204.4°C (peak 210.3°C) followed by final overlapping endotherms at onset 220.8°C (peak 237.7°C).

[0130] Polarized light microscopy for Form 6 from 1,4-Di oxane showed small lath-like particles.

[0131] Table 6 provides the XRPD characteristic peaks of Form 6 (Pattern 6).

[0132] Table 6: XRPD Peak List of Pattern 6

[0133]

[0134]

[0135] Form 7 of Compound I is anhydrous and can be obtained from multiple solvent systems and crystallization conditions. Low residual solvent is present in Form 7; no significant mass losses in TGA prior to degradation.

[0136] The TGA of Form 7 from ethyl formate showed the following: No significant mass losses prior to the onset of degradation. The simultaneous DSC showed the following: A very shallow broad endotherm at onset 104.4 °C (peak 120.0°C). A final melting endotherm at onset 233.1°C (peak 236.9°C).

[0137] Polarized light microscopy for Form 7 from acetic acid showed very small lath-like particles with signs of a thin rod-like morphology.

[0138] Table 7 provides the XRPD characteristic peaks of Form 7 (Pattern 7).

[0139] Table 7: XRPD Peak List of Pattern 7

[0140]

[0141]

[0142] Form 8 of Compound I is obtained from N,N-dimethylacetamide, or N,N-dimethylacetamide / water. A similar form, Form 8b is obtained from drying Form 16. Greater than 1 mole equivalent of N,N-dimethylacetamide present in Form 8. Form 8 will be desolvated or dehydrated to a poorly crystalline material similar to Form 18 after heating to 125°C and to poorly crystalline Form 18 after heating to 190°C. Form 8 is believed to be

[0143] N,N-dimethylacetamide solvate.

[0144] The TGA of Form 8 dried from N,N-dimethylacetamide showed an initial 1.86% mass loss likely due to unbound solvent and / or water, a stepwise mass loss of 5.3% (theoretically 0.5 mole equiv. DMA) between 72 and 120°C and a further 8.3% (theoretically

[0145] O.81 mole equiv. DMA) mass loss between 139 and 200° C. The simultaneous DSC showed endotherms associated with the mass losses onsets 95.4°C (peak 98.4°C) and 161.9°C (peak 174.1°C). A final melting endotherm of 235.9°C (peak 244.5°C).

[0146] Polarized light microscopy for Form 8 from N,N-dimethylacetamide showed particles with a lathdike morphology.

[0147] Tables 8-10 provides the XRPD characteristic peaks of Form 8 (Pattern 8), Pattern 8a,

[0148] Pattern 8b, respectively.

[0149] Table 8: XRPD Peak List of Pattern 8

[0150]

[0151] Table 9: XRPD Peak List of Pattern 8a

[0152]

[0153] Table 10: XRPD Peak List of Pattern 8b

[0154]

[0155] Form 9 of Compound I is obtained from for example acetonitrile, or acetonitrile / DIPE. Low solvent content was detected in Form 9 by 'H NMR in deuterated THF. Form 9 will be dehydrated to Form 17 (very similar to Form 9) upon heating to 110°C and to Form 7 upon heating to 180°C, or converted to Form 7 after extensive drying. Form 9 is believed to be hydrate. Water is likely weakly bound as Form 9 converted to Form 7 with extensive drying.

[0156] The TGA of Form 9 from acetonitrile showed an initial 6.0% mass loss between 30 and 88° C, likely due to both unbound and bound solvent and / or water. The simultaneous DSC showed an endotherm associated with the TGA mass loss, a small endotherm present at onset 121.6°C (peak 128.3°C) followed by an exotherm at onset 150.2°C (peak 162.6°C), and a final melting endotherm of 229.8°C (peak 236.8°C).

[0157] Polarized light microscopy for Form 9 obtained from acetonitrile showed very small particles with no clear morphology.

[0158] Table 11 provides the XRPD characteristic peaks of Form 9 (Pattern 9).

[0159] Table 11: XRPD Peak List of Pattern 9

[0160]

[0161] Form 10 of Compound I is obtained from for example 1,2-dimethoxy ethane. Form 10 contains greater than 0.5 mole equivalents of 1,2- dimethoxy ethane. It can be desolvated to Form 18 upon heating to 180°C. Form 10 is believed to be 1 ,2-Dimethoxy ethane solvate

[0162] The TGA of Form 10 showed an initial 1.86% mass loss between 32 and 98° C, likely due to both unbound solvent / water, a stepwise 3.2% mass loss (theoretically 0.29 mole equiv.

[0163] 1,2- dimethoxyethane) between 98 and 153°C, likely due to bound solvent and a further 1.4% (theoretically 0.12 mole equiv. 1,2-dimethoxy ethane) mass loss between 210 and 235°C. The simultaneous DSC showed endotherms associated with the TGA mass losses at onsets 88.0°C (peak 101.5°C), 118.3°C (127.4°C) and 220.9°C (226.0°C), and a final endotherm of 234.6°C (peak 240.4°C) is also present.

[0164] Polarized light microscopy for Form 10 from 1,2-dimethoxy ethane showed particles with a thin lath-like morphology.

[0165] Tables 12-13 provide the XRPD characteristic peaks of Form 10 (Pattern 10) and Pattern 10a, respectively.

[0166] Table 12: XRPD Peak List of Pattern 10

[0167]

[0168] Table 13: XRPD Peak List of Pattern 10a

[0169]

[0170] Form 11 of Compound I is obtained from dimethylsulphoxide. About 3 mole equivalents dimethylsulphoxide was detected by 'H NMR. Form 11 will be desolvated or dehydrated to poorly crystalline Form 18 upon heating to either 180°C or 200°C. It is believed that Form 11 is dimethylsulphoxide solvate.

[0171] The TGA of Form 11 showed a 2.9% mass loss up to 81°C, likely due to unbound solvent or water, followed by stepwise mass losses of 15.3% between 99 and 154°C and 8.9% between 153.8 and 215.0°C, likely due to bound solvent. The simultaneous DSC showed endotherms associated with the mass losses at onset 132.5°C (peak 134.4°C) and onset 186.0°C (peak 202.5°C) with a final melting endotherm at onset 232.5°C (peak 239.5°C).

[0172] Polarized light microscopy for Form 11 from dimethylsulphoxide showed small particles with a lath-like morphology.

[0173] Table 14 provides the XRPD characteristic peaks of Form 11 (Pattern 11).

[0174] Table 14: XRPD Peak List of Pattern 11

[0175]

[0176] Form 12 of Compound I is obtained from dehydration of Form 1 after heating to 160°C. It has low residual solvent and shows no significant mass losses in TGA prior to degradation. Form 12 is anhydrous.

[0177] The TGA of Form 12 showed no significant mass losses prior to degradation. The simultaneous DSC showed an endotherm at onset 231.0°C (peak 237.3°C) with an initial shoulder at peak 223.6°C. The thermal events are consistent with those observed for Form 1 after the dehydration event. Polarized light microscopy for Form 12 (from dehydration of Fl) showed small, aggregated particles with a thin rod-like morphology7.

[0178] Table 15 provides the XRPD characteristic peaks of Form 12 (Pattern 12).

[0179] Table 15: XRPD Peak List of Pattern 12

[0180]

[0181]

[0182] Form 13 of Compound I is obtained from for example acetone. Acetone is detected by!H NMR and Form 13 undergoes stepwise mass loss in TGA at about 145°C. Form 13 can be desolvated and / or dehydrated to predominantly Form 18 upon heating to 180°C. Form 13 is likely to be unstable acetone solvate or mixed solvate / hydrate. Form 13 can also be dried to Form 6 with traces of Form 2.

[0183] The TGA of Form 13 showed a 2.4% mass loss up to 89°C likely due to unbound solvent / water, followed by 2.5% and 3.5% mass losses between 89 and 186°C. The simultaneous DSC showed endotherms at onset 96.7 °C (peak 112.3°C) and onset 161.1°C (peak 165.0°C) associated with the mass losses in the TGA. A further small endotherm is present at onset 211.9 °C (peak 214.8 °C) and a final melting endotherm is present at onset 232.0°C (peak 241.0°C).

[0184] Polarized light microscopy for Form 13 from acetone showed very small, aggregated particles with no clear morphology.

[0185] Table 16 provides the XRPD characteristic peaks of Form 13 (Pattern 13).

[0186] Table 16: XRPD Peak List of Pattern 13

[0187]

[0188] Form 14 of Compound I is obtained from for example ethanol, 1-propanol. It is unstable and will be dried to Form 4. Form 14 is likely an unstable solvate or mixed solvate / hydrate.

[0189] Table 17 provides the XRPD characteristic peaks of Form 14 (Pattern 14).

[0190] Table 17: XRPD Peak List of Pattern 14

[0191]

[0192] Form 15 of Compound I is obtained from for example tetrahydrofuran, and is tetrahydrofuran solvate. Form 15 contains greater than 1 mole equivalent of tetrahydrofuran confirmed by 'H NMR. Form 15 can be converted to a mixture of Form 18 and Form 2 upon heating to 180°C.

[0193] The TGA showed a 0.9% mass loss up to 73°C (likely due to unbound solvent I water) followed by a stepwise mass loss of 10.3% between 73 and 110°C and a further loss of 3.8% between 109.8 and 175.10°C (likely due to bound solvent). A final loss of 2.3% is present between 212 and 237°C associated with the melting point. The simultaneous DSC showed an endotherm associated with the first TGA mass loss at onset 81.3°C (peak 90.2°C) followed by an exotherm at onset 104.4°C (peak 124.5°C). A small endotherm is present at onset 196.8°C (peak 200.3°C) and a final melting endotherm is present at onset 215.4 (peak 225.8C).

[0194] Polarized light microscopy for Form 15 from tetrahydrofuran showed aggregated particles with a plate-like morphology.

[0195] Table 18 provides the XRPD characteristic peaks of Form 15 (Pattern 15).

[0196] Table 18: XRPD Peak List of Pattern 15

[0197]

[0198] Form 16 of Compound I is obtained from for example N,N-dimethylacetamide / water.

[0199] It contains greater than 1 mole equivalent of N,N-dimethylacetamide (DMA) confirmed by!H NMR. Form 16 can be desolvated to predominantly Form 18 upon heating to 180°C, or dried to a material similar to Form 8, assigned as Form 8b. It is believed that Form 16 is N,N-dimethylacetamide solvate or potential mixed solvate / hydrate.

[0200] The TGA of Form 16 showed a 0.6% mass loss up to 64.7°C (likely due to unbound solvent / water followed by stepwise mass losses of 5.4% and 5.5% between 98°C and 139°C, and 140°C and 199°C respectively, likely due to bound solvent. The simultaneous DSC showed the endotherms associated with the mass losses at onset 107.8 °C (peak 123.4°C) and 164.8°C (peak 178.2°C). A further small endotherm is present at onset 206.3 °C (peak 208.1 °C) and a final melting endotherm is present at onset 220.7°C (peak 235.7°C).

[0201] Polarized light microscopy for Form 16 obtained from DMA / water showed aggregated particles with signs of a plate-like morphology.

[0202] Table 19 provides the XRPD characteristic peaks of Form 16 (Pattern 16).

[0203] Table 19: XRPD Peak List of Pattern 16

[0204]

[0205]

[0206] Form 17 of Compound I is obtained from heating Form 9 to 110°C. Diffractogram of

[0207] Form 17 is very similar to Form 9 with small peak changes and shifts upon heating. Form 17 is likely to be a transient form obtained upon removal of / solvent water, as Form 7 is ultimately obtained upon heating or extensive drying of Form 9.

[0208] Table 20 provides the XRPD characteristic peaks of Form 17 (Pattern 17).

[0209] Table 20: XRPD Peak List of Pattern 17

[0210]

[0211] Form 18 of Compound I is anhydrous, and obtained from complete or partial conversion to Form 18 by heating Form 6, Form 10, Form 11, Form 13, Form 15, or Form 8b to 180-200°C.

[0212] Table 21 provides the XRPD characteristic peaks of Form 18 (Pattern 18).

[0213] Table 21: XRPD Peak List of Pattern 18

[0214]

[0215]

[0216] Form 19 of Compound I is obtained from slurrying Form 3 in 2 -propanol: water

[0217] (50:50%v / v) at 20 and 50°C and in methanol: water (50:50%v / v) at 20°C, or slurrying Form 3 in water. Form 19 is unstable and converts to Form 3 when dried.

[0218] The TGA of Form 19 showed an early mass loss of 3.2% between 27 and 94°C likely due to the loss of both unbound and weakly bound water. The simultaneous DSC showed an initial endotherm at onset 35.6°C (peak 58.6°C) associated with the mass loss. A melting endotherm is present at onset 240.6°C (peak 246.6°C).

[0219] Table 22 provides the XRPD characteristic peaks of Form 19 (Pattern 19).

[0220] Table 22: XRPD Peak List of Pattern 19

[0221]

[0222] In some preferred embodiments, the polymorphs of this invention are characterized below:

[0223] Form 1, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.7, 10.2, 11.9, 14.8, 15.4, 20.5, 22.7, and / or 24.0°0 using CuKa radiation;

[0224] Form 2, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 7.5, 8.8, 11.9, 14.1, 15.1, 15.8. 17.8. 20.3, and / or 24.3°0 using CuKa radiation;

[0225] Form 3, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.9, 14.8, 15.0, 22.6, 23.2, and / or 25.0°0 using CuKa radiation;

[0226] Form 4, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 14.7, 15.3, 22.5, 24.6, and / or 26. CFO using CuKa radiation;

[0227] Form 5, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.0, 15.0, 21.2, 22.8, and / or 24.3°0 using CuKa radiation;

[0228] Form 6, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.8, 9.7, 13.2, 15.0, 19.5, 22.6. 23.6. 26.2, and / or 3O.3°0 using CuKa radiation;

[0229] Form 7, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.8, 15.4, 23.1, 25.9, and / or 29.4°0 using CuKa radiation;

[0230] Form 8, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 7.9, 14.8. 15.3. 19.8. and / or 22.1°0 using CuKa radiation;

[0231] Form 8a, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 7.9, 15.0, 15.8, 22.6, and / or 31.1°0 using CuKa radiation;

[0232] Form 8b, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 13.1. 15.3. 22.3. 23.0, and / or 31.6°0 using CuKa radiation;

[0233] Form 9, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.4, 14.9, 19.9, 21.9, and / or 23.3°0 using CuKa radiation;

[0234] Form 10, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 7.2, 20.4, 22.7, 24.2, and / or 29.4°0 using CuKa radiation;

[0235] Form 10a, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 7.3, 14.8, 17.8, 22.8, and / or 29.5°0 using CuKa radiation;

[0236] Form 11, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 13.7. 16.0, 24.9, 30.0, and / or 38.4°0 using CuKa radiation;

[0237] Form 12, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 3.5, 7.1, 14.8, 15.5, and / or 22.7°0 using CuKa radiation;

[0238] Form 13, characterized by having one or more X-ray pow der diffraction (XRPD) peaks at approximately 13.9, 19.9, 22.5, 23.6, and / or 25.O°0 using CuKa radiation;

[0239] Form 14, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.6, 20.1, 23.5, 26.0, and / or 29.2°0 using CuKa radiation;

[0240] Form 15, characterized by having one or more X-ray pow der diffraction (XRPD) peaks at approximately 9.1, 13.0, 15.3, 17.7, 21.4, and / or 22.5°0 using CuKa radiation;

[0241] Form 16, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 8.2, 14.7, 15.9, 19.7, and / or 23.2°9 using CuKa radiation;

[0242] Form 17, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.6, 14.9, 15.7, 20.0, and / or 23.4°9 using CuKa radiation;

[0243] Form 18, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 13.2. 14.4. 15.0, 16.2, and / or 22.4°9 using CuKa radiation;

[0244] Form 19, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.7, 14.9, 20.5, 23.9, and / or 25.8°9 using CuKa radiation.

[0245] In yet preferred embodiments, the polymorphs of this invention are characterized below:

[0246] Form 1, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 6.7, 10.2, 11.9, 14.8, 15.4, 20.5, 22.7, and / or 24.0°9 using CuKa radiation;

[0247] Form 2, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 7.5, 8.8, 11.9, 14.1, 15.1, 15.8, 17.8, 20.3, and / or 24.3°9 using CuKa radiation;

[0248] Form 3, characterized by having three or more X-ray pow der diffraction (XRPD) peaks at approximately 6.9, 14.8, 15.0, 22.6, 23.2, and / or 25.0°9 using CuKa radiation;

[0249] Form 4, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 14.7, 15.3, 22.5, 24.6, and / or 26.0°9 using CuKa radiation;

[0250] Form 5, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 6.0, 15.0, 21.2, 22.8, and / or 24.3°9 using CuKa radiation;

[0251] Form 6, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 6.8, 9.7, 13.2, 15.0, 19.5, 22.6, 23.6, 26.2, and / or 30.3°9 using CuKa radiation;

[0252] Form 7, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 6.8, 15.4, 23.1, 25.9, and / or 29.4°9 using CuKa radiation;

[0253] Form 8, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 7.9, 14.8, 15.3, 19.8, and / or 22.1°9 using CuKa radiation;

[0254] Form 8a, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 7.9, 15.0, 15.8, 22.6, and / or 31.1°9 using CuKa radiation;

[0255] Form 8b, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 13.1. 15.3. 22.3. 23.0, and / or 31.6°0 using CuKa radiation;

[0256] Form 9, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 6.4, 14.9, 19.9, 21.9, and / or 23.3°9 using CuKa radiation;

[0257] Form 10, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 7.2, 20.4, 22.7, 24.2, and / or 29.4°9 using CuKa radiation;

[0258] Form 10a, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 7.3, 14.8, 17.8, 22.8, and / or 29.5°9 using CuKa radiation;

[0259] Form 11, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 13.7. 16.0, 24.9, 30.0, and / or 38.4°0 using CuKa radiation;

[0260] Form 12. characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 3.5, 7.1, 14.8, 15.5, and / or 22.7°0 using CuKa radiation;

[0261] Form 13, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 13.9, 19.9, 22.5, 23.6, and / or 25.0°9 using CuKa radiation;

[0262] Form 14, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 6.6, 20.1, 23.5, 26.0, and / or 29.2°9 using CuKa radiation;

[0263] Form 15, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 9.1, 13.0, 15.3, 17.7, 21.4, and / or 22.5°0 using CuKa radiation;

[0264] Form 16, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 8.2, 14.7, 15.9, 19.7, and / or 23.2°9 using CuKa radiation;

[0265] Form 17, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 6.6, 14.9, 15.7, 20.0, and / or 23.4°9 using CuKa radiation;

[0266] Form 18, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 13.2. 14.4. 15.0. 16.2, and / or 22.4°0 using CuKa radiation;

[0267] Form 19, characterized by having three or more X-ray powder diffraction (XRPD) peaks at approximately 6.7, 14.9, 20.5, 23.9, and / or 25.8°9 using CuKa radiation.

[0268] Pharmaceutical Compositions

[0269] Also provided herein are pharmaceutical compositions comprising a cry s tai I me form of Compound I described herein; and a pharmaceutically acceptable carrier. In embodiments, the carrier can comprise an excipient.

[0270] The phrase “pharmaceutically acceptable’' is employed herein to refer to those ligands, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. The compositions described herein can be formulated for any form of administration. In various cases, the composition is for oral administration. In various cases, the composition is in tablet form.

[0271] The phrase “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. As used herein the language “pharmaceutically acceptable carrier” includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as com starch, potato starch, and substituted or unsubstituted 0-cyclodextrin; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations. In certain embodiments, pharmaceutical compositions provided herein are non-pyrogenic, i.e., do not induce significant temperature elevations when administered to a patient.

[0272] Wetting agents, emulsifiers, and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening,flavoring, and perfuming agents, preservatives and antioxidants can also be present in the compositions as excipients.

[0273] Examples of pharmaceutically acceptable antioxidants as excipient include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA). butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0274] A pharmaceutical composition may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include tonicity-adjusting agents, such as sugars and the like into the compositions. In addition, prolonged absorption of an injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

[0275] In some cases, in order to prolong the effect of one or more compounds provided herein, it is desirable to slow the absorption of the compound from subcutaneous or intramuscular injections. For example, delayed absorption of a parenterally administered compound can be accomplished by dissolving or suspending the compound in an oil vehicle.

[0276] In some cases, the pharmaceutical composition is in a dosage form for injection, preferably a long-acting injectable form such as crystal aqueous suspension, in-situ gel, polymeric matrices, and nanosuspension. The injectable dosage form used in this invention is intended to include all injection forms suitable for formulating the polymorphs disclosed herein.

[0277] The composition should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents,for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.

[0278] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the methods of preparation include freeze-drying (lyophilization), which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The methods of preparing sterile injectable solutions include terminal sterilization. Namely, the pharmaceutical composition can be prepared non-aseptically and then subjected to a terminal sterilization operation to have a sterile product that is suitable for administration to a subject. The sterilization operation used for this invention includes all sterilization techniques currently available in the market, being developed, and that will be developed, such as heat, filtration treatment, irradiation (such as gamma-irradiation or electron-beam radiation), and aseptic recrystallization.

[0279] Injectable depot forms can be made by forming microencapsule or nanoencapsule matrices of a compound provided herein in biodegradable polymers such as polylactidepoly glycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes, microemulsions or nanoemulsions, which are compatible with body tissue.

[0280] In some embodiments, the polymorphs and salts disclosed herein are prepared with carriers that will protect the therapeutic compounds against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such

[0281] formulations can be prepared using standard techniques, or obtained commercially, e.g., from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to selected cells with monoclonal antibodies to cellular antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811, which is incorporated herein by reference in its entirety’.

[0282] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0283] Methods of Use

[0284] The present application also provides therapeutic methods and uses comprising administering the forms of Compound I as described herein, alone or in combination with other therapeutic agents or palliative agents.

[0285] In some embodiments, provided is a method for the treatment of one or more inflammatory-related diseases or disorders in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a form of Compound I as described herein.

[0286] In some embodiments, provided is a method for the treatment of one or more inflammatory-related diseases or disorders in a subject in need thereof, comprising administering to the subject an amount of a form of Compound I as described herein, in combination with an amount of an additional therapeutic agent, which amounts are together effective in treating said one or more inflammatory -related diseases or disorders.

[0287] In some embodiments, provided is also a method for the treatment of a disease or disorder mediated by calcineurin in a subject, comprising administering to the subject a form of Compound I as described herein, in an amount that is effective for treating said disease or disorder, in particular an inflammatory-related disease or disorder.

[0288] In some embodiments, provided is also a method of inhibiting calcineurin in a subject, comprising administering to the subject a form of Compound I as described herein, in an amount effective to inhibit calcineurin.

[0289] The treatment regimen for the compound of the invention that is effective to treat one or more inflammatory-related diseases or disorders patients may vary according to factors such as the disease state, age, and weight of the patient, and the ability of the therapy to elicitan anti- inflammatory response in the subject. While an embodiment of any of the aspects of the present application may not be effective in achieving a positive therapeutic effect in every subject, it should do so in a statistically significant number of subjects as determined by any statistical test known in the art such as the Student's t-test, the chi2-test the U-test according to Mann and Whitney, the Kruskal -Wallis test (H-test), Jonckheere-Terpstrat-testy and the Wilcon on-test.

[0290] In some embodiments, this application includes a method of treating a disease or disorder characterized by elevated calcineurin activity in a subj ect in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention. In some embodiments, the application includes a method of treating a disease or disorder characterized by elevated calcineurin activity in cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention.

[0291] In some embodiments, the application includes a method of treating a disease or disorder in a subject in need thereof, comprising systemically administering to the subject a therapeutically effective amount of a compound disclosed herein. In some embodiments, the application includes a method of treating a disease or disorder in a subject in need thereof, comprising parenterally administering to the subject a therapeutically effective amount of a compound disclosed herein. In some embodiments, the application includes a method of treating a disease or disorder in a subject in need thereof, comprising orally administering to the subject a therapeutically effective amount of a compound disclosed herein.

[0292] In some embodiments, parenteral administration includes, but is not limited to, subcutaneous administration, intramuscular administration, intravenous administration, and intrathecal administration. In some embodiments, parenteral administration is subcutaneous administration. In some embodiments, parenteral administration is intramuscular administration. In some embodiments, parenteral administration is intravenous administration. In some embodiments, parenteral administration is intrathecal administration.

[0293] In some embodiments, the application includes a method of treating a disease or disorder in a subject in need thereof, comprising administering via inhalation to the subject a therapeutically effective amount of a compound disclosed herein.

[0294] In some embodiments, the application includes a method of treating a disease or disorder in a subject in need thereof, comprising intranasally administering to the subject a therapeutically effective amount of a compound disclosed herein.

[0295] In some embodiments, the application includes a method of treating a condition or disorder associated with abnormal Calcineurin activity' in a subject in need, wherein the method comprises administering to the subject a therapeutically effective amount of the compound of the invention.

[0296] In some embodiments, the application includes a method of treating a disease or disorder characterized by elevated calcineurin activity' in a subj ect in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention. In some embodiments, the application includes a method of treating a disease or disorder characterized by elevated calcineurin activity in skin cells in a subject in need thereof, comprising administering to the subj ect a therapeutically effective amount of a compound of the invention. In some embodiments, the application includes a method of treating a disease or disorder characterized by elevated calcineurin activity in ocular cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention.

[0297] In some embodiments, the application also provides for a method for delaying in patient the onset of an inflammatory-related disease or disorder comprising the administration of a therapeutically effective amount of the compound of the invention to a patient in need thereof.

[0298] In some embodiments, the application also provides a method of protecting a kidney by reducing immunosuppression-induced nephrotoxicity' in a subject in need, wherein the method comprises administering to the subject a therapeutically effective amount of the compound of the invention. Preferably, a kidney is a transplanted kidney.

[0299] In some embodiments, the compound of the invention may be administered in combination with a standard of care agent. In some embodiments, the compound of the invention may be administered in combination with an additional therapeutic agent or treatment.

[0300] In some embodiments, the compound of the invention exhibits reduced nephrotoxicity compared to the existing CNIs as described herein, such as tacrolimus. In some embodiments,the compound of the invention exhibits reduced nephrotoxicity compared to the existing CNIs as described herein, such as tacrolimus, for the treatment of the same condition or disease.

[0301] In some embodiments, the compound of the invention exhibits improved bioavailability compared to the existing CNIs as described herein, such as tacrolimus, for the treatment of the same condition or disease.

[0302] In some embodiments, the compound of the invention exhibits a reduced variability of exposure compared to the existing CNIs as described herein, such as tacrolimus, for the treatment of the same condition or disease.

[0303] In some embodiments, the compound of the invention exhibits reduced food effects compared to the existing CNIs as described herein, such as tacrolimus, for the treatment of the same condition or disease.

[0304] In some embodiments, the compound of the invention exhibits reduced maximum-to-minimum concentration (Cmax / Cmin) ratio compared to the existing CNIs as described herein, such as tacrolimus, for the treatment of the same condition or disease.

[0305] In some embodiments, the compound of the invention exhibits reduced patient nonadherence compared to the existing CNIs as described herein, such as tacrolimus, for the treatment of the same condition or disease.

[0306] Indications

[0307] The forms of Compound I. compositions, methods, and kits of the invention can be used to treat diseases or disorders, preferably inflammatory-related diseases or disorders. In some embodiments, the application includes a compound for use in the treatment and / or prevention of inflammatory-related diseases or disorders. In some embodiments, the application provides use of a compound for the manufacture of a medicament for treating inflammation-related diseases or disorders. The application also provides a method of treatment of systemic disease or disorder, which comprises administering to a subject in need thereof a therapeutically effective amount of the compound of the invention. The compound of the invention can be administered to the subject in need through any route of administration as described herein. In some cases, it is systemically administered. In some cases, it is orally administered. In some cases, it is administered via subcutaneous administration. In some cases, it is administered via ophthalmic drug administration (e.g., eyedrops). In some cases, it is administered via pulmonary drug delivery (e.g., inhaler). In some cases, it is administered through topical administration.

[0308] In some embodiments, the inflammation-related disease or disorder includes but is not limited to periodontitis, keratoconjuncitivitis sicca, rheumatoid arthritis, osteoarthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, traumatic arthritis, rubella arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis, graft versus host disease, systemic lupus erythematosus, cutaneous lupus erythematosus, toxic shock syndrome, irritable bowel syndrome, muscle degeneration, allograft rejections, pancreatitis, insulitis, glomerulonephritis, diabetic nephropathy, renal fibrosis, chronic renal failure, gout, leprosy, acute synovitis, Reiter's syndrome, gouty arthritis. Behcet's disease, spondylitis, endometriosis, non-articular inflammatory conditions, such as itch. Intervertebral disk syndrome conditions, bursitis, tendonitis, tenosynovitis or fibromyalgia syndrome; and acute or chronic pain, including but not limited to neurological pain, neuropathies, polyneuropathies, diabetes-related polyneuropathies, trauma, migraine, tension and cluster headache, Holton's disease, varicose ulcers, neuralgias, Musculo-skeletal pain, osteotraumatic pain, fractures, algodystrophy, spondylarthritis, fibromyalgia, phantom limb pain, back pain, vertebral pain, post-surgery pain, herniated intervertebral disc— induced sciatica, cancer related pain, vascular pain, visceral pain, childbirth, HIV-related pain, a metabolic disease, a chemotherapy / radiation related complication; diabetes type 1: diabetes type II; a liver disease; a gastrointestinal disorder; an ophthalmological disease; allergic conjunctivitis; diabetic retinopathy; Sjogren's syndrome; uveitis; a renal disease; HV -related cachexia; cerebral malaria; anky losing spondylitis; leprosy; anemia; fibromyalgia, kidney failure, stroke, chronic heart failure, endotoxemia, reperfusion injury, ischemia reperfusion, myocardial ischemia, restenosis, thrombosis, angiogenesis, Coronary Heart Disease, Coronary Artery Disease, acute coronary syndrome, Takayasu arteritis, cardiac failure such as heart failure, aortic valve stenosis, cardiomyopathy, myocarditis, vasculitis, vascular restenosis, valvular disease or coronary' artery bypass: hypercholesteremia, diseases or conditions related to blood coagulation or fibrinolysis, such as for example, acute venous thrombosis, pulmonary embolism, thrombosis during pregnancy, hemorrhagic skin necrosis, acute or chronic disseminated intravascular coagulation (DIC), dot formation from surgery, long bed rest or long periods of immobilization, venous thrombosis, fulminant meningococcemia, acute

[0309] thrombotic strokes, acute coronary occlusion, acute peripheral arterial occlusion, massive pulmonary embolism, axillary vein thrombosis, massive iliofemoral vein thrombosis, occluded arterial or venous cannulae, cardiomyopathy, veno-occlusive disease of the liver, hypotension, decreased cardiac output, decreased vascular resistance, pulmonary hypertension, diminished lung compliance, leukopenia or thrombocytopenia, or atherosclerosis.

[0310] In some embodiments, the invention can be used to treat the diseases or disorders that are targets of calcineurin inhibitors, including allergic conjunctivitis, aplastic anemia, atopic dermatitis, Behcet’s disease, dry' eye / keratoconjunctivitis, graft-versus-host disease, interstitial pneumonia, Kawasaki disease, keratitis, lupus nephritis, nephrotic syndrome, psoriasis, rheumatoid arthritis, transplant rejection, ulcerative colitis, and uveitis. In additional embodiments, the invention can be used to treat diseases or disorders including autoimmune hepatitis, bullous pemphigoid, Crohn’s disease, FS glomerulosclerosis, Goodpasture’s disease, Graves disease, IgA nephropathy, idiopathic inflammatory myositis, membranous glomerulonephritis, minimal change disease, multiple sclerosis, myasthenia gravis, pemphigoid vulgaris, Sjogren's syndrome, systemic sclerosis, and type 1 diabetes.

[0311] In some embodiments, the application includes a method of preventing organ transplant rejection. In some embodiments, the organ transplant is kidney, liver, heart, lung, pancreas, or intestine. In some embodiments, the application includes a method of treating an infection. In some embodiments, an infection is a fungal infection.

[0312] In some embodiments, the application includes a method of preventing organ transplant rejection and the organ is preferably a kidney. In some embodiments, the application includes a method of treating a disorder or condition associated with kidney transplant in a subject in need. The method comprises administering to the subject in need a therapeutically effective amount of the compound of the invention. Preferably, the method comprises systematically administering to the subject in need a therapeutically effective amount of the compound of the invention, e g., via oral administration, intravenous administration, intramuscular administration, subcutaneous administration, inhalation administration, or rectal administration; preferably, oral or subcutaneous administration.

[0313] In some embodiments, the application includes a method of treating or ameliorating lupus nephritis in a subject in need. In some embodiments, the application includes a methodof treating a disorder or condition associated with lupus nephritis in a subject in need. In some embodiments, the application includes a method of treating or ameliorating ANCA-associated vasculitis in a subject in need. In some embodiments, the application includes a method of treating a disorder or condition associated with ANCA-associated vasculitis in a subject in need. The method comprises systematically administering to the subject in need a therapeutically effective amount of the compound of the invention, e.g., via oral administration, intravenous administration, intramuscular administration, subcutaneous administration, inhalation administration, or rectal administration; preferably, oral or subcutaneous administration.

[0314] In some embodiments, the application includes methods of treating inflammatory-related diseases or disorders, including skin or ocular disorders. In some embodiments, the application includes a compound for use in the treatment and / or prevention of inflammatory-related diseases or disorders. Thus, in one embodiment, the application provides use of a compound for the manufacture of a medicament for treating and / or inflammatory-related diseases or disorders. The application also provides a method of treatment of a skin disease or disorder, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the application. The application also provides a method of treatment of an ocular disease or disorder, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the application.

[0315] In some embodiments, the inflammatory -related disease or disorder is a skin disease or disorder. In some embodiments, a skin disease or disorder is selected from the group consisting of psoriasis, dermatitis, eczema (also known as atopic dermatitis), hives, lichen planus, lichen scleroses, vitiligo, discoid lupus, cutaneous lupus erythematosus and pity riasis alba. In some embodiments, a skin disease or disorder is psoriasis. In some embodiments, a skin disease or disorder is dermatitis. In some embodiments, a skin disease or disorder is eczema. In some embodiments eczema is seborrheic eczema. In some embodiments, dermatitis is selected from the group consisting of contact dermatitis, atopic dermatitis, nummular dermatitis, seborrheic dermatitis, and stasis dermatitis. Preferably, the compound of the invention is administered topically.

[0316] In some embodiments, an inflammatory-related disease or disorder is an ocular disease or disorder. In some embodiments an ocular disease or disorder is selected from thegroup consisting of dry eye syndrome (DES), Sjogren's syndrome, uveitis (such as refractory' anterior uveitis), conjunctivitis (pink eye), keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), autoimmune disorders of the ocular surface, including cicatrizing conjunctivitis, blepharitis, and scleritis. In some embodiments an ocular disease or disorder is dry' eye syndrome (DES). In some embodiments an ocular disease or disorder is Sjogren's syndrome. In some embodiments an ocular disease or disorder is uveitis, preferably refractory7anterior uveitis. Preferably, the compound of the invention is administered via ophthalmic drug administration (e.g., eye drops).

[0317] In some embodiments, the application includes a method of treating an infection. In some embodiments, an infection is a fungal infection. In some embodiments, a fungal infection is a nail fungal infection. In some embodiments, a fungal infection is a toenail fungal infection. In some embodiments, a fungal infection is a fingernail fungal infection.

[0318] In some embodiments, the application includes the methods of treating inflammatory -related diseases or disorders, including pulmonary disorders. In some embodiments, the application includes a compound for use in the treatment and / or prevention of inflammatory-related diseases or disorders. Thus, in one embodiment, the application provides use of a compound for the manufacture of a medicament for treating and / or inflammatory' related diseases or disorders. The application also provides a method of treatment of a pulmonary' disease or disorder, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the application.

[0319] In some embodiments, inflammatory -related disease or disorder is a pulmonary' disease or disorder. In some embodiments, a pulmonary' disease or disorder is selected from the group consisting of allergic rhinitis, asthma, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, emphysema, bronchitis, mucus hypersecretion, silicosis, SARS infection and respiratory’ tract inflammation.

[0320] In some embodiments, the application includes a method of preventing organ transplant rejection. In some embodiments, the organ is lung. In some embodiments, the application includes a method of treating a disorder or condition associated with lung transplant in a subject in need. The method comprises administering to the subject a therapeutically7effective amount of the compound of the invention. Conditions requiring lung transplant include but are not limited to chronic obstructive pulmonary’ disease (COPD),cystic fibrosis, idiopathic pulmonary fibrosis (IPF), pulmonary hypertension. In some cases, the subject is a recipient of transplanted lung. In some cases, the disorder or condition associated with lung transplant is a post-transplant complication. In some cases, the disorder or condition associated with lung transplant is a post-transplant complication including graft rejection wherein the recipient’s immune system treats the transplanted lung as foreign and mounts an immune response, i.e., graft-versus-host disease (GvHD), infections, bronchiolitis obliterans syndrome (BOS), and other postoperative complications.

[0321] In some embodiments, the application includes a method of treating a pulmonary disease or disorder in a subject in need. In some embodiments, the subject is diagnosed with asthma, such as steroid-unresponsive asthma. In some embodiments, the pulmonary disease or disorder includes asthma (such as steroid-unresponsive asthma), chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, bronchiectasis, sarcoidosis, interstitial lung disease (ILD), pneumonia, tuberculosis. In some embodiments, the pulmonary disease or disorder is asthma, such as steroid-unresponsive asthma. Preferably, the compound of the invention is administered systematically such as oral or subcutaneous administration. Preferably, the compound of the invention is administered via pulmonary drug delivery such as using an inhaler.

[0322] As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, references to “the method” includes one or more methods, and / or steps of the type described herein which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.

[0323] The term “comprising”, which is used interchangeably with “including”, “containing”, or “characterized by”, is inclusive or open-ended language and does not exclude additional, unrecited elements or method steps.

[0324] The phrase “consisting of’ excludes any element, step, or ingredient not specified in the claim. The phrase “consisting essentially of’ limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. The present disclosure contemplates embodiments of the invention compositions and methods corresponding to the scope of each of these phrases. Thus, a composition or method comprising recited elements or steps contemplates particular

[0325] embodiments in which the composition or method consists essentially of or consists of those elements or steps.

[0326] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are now described.

[0327] Examples

[0328] Preparation of Amorphous Material

[0329] The following procedure was used for preparation of poorly crystalline material. Approximately, 875 mg of Compound I was dissolved in 110 rnL of 1,4-dioxane: water (81.6:18.4%v / v). 3.1mL of solution was pipetted into each of 35 scintillation vials to obtain approximately 25 mg per vial. The samples were frozen and then lyophilized for 1 day. After lyophilization, the samples were further dried at 40°C under vacuum for 1 day in order to remove residual solvent and water. A sample was then analyzed by XRPD and 1H NMR analysis. The lyophilization process resulted in a poorly crystalline material with weak diffraction peaks predominantly consistent with Form 6. 1H NMR confirmed the material to be consistent with the reference NMR spectrum for Compound I free acid with 0.02 mole equivalents (0.23 wt. %) of 1,4-dioxane present.

[0330] Solvent Solubility

[0331] The following procedure was employed: To 20 mL scintillation vials, each containing ca. 25 mg of poorly crystalline Compound I material, the respective solvent system was added in aliquots until the material dissolved or 200 volumes had been added. Aliquot sizes were as follows: 5 volume aliquots up to 2.0 mL, 20 volume aliquots up to 5 mL. The assessment was carried out at 25°C. Between each addition, the samples were shaken manually and observed for dissolution before the next aliquot was added as required.

[0332] The approximate solvent solubility' assessment showed low solubility' (< 5 mg / mL) in a large number of the solvent systems assessed. Moderate solubility (5 - 20 mg / mL) was observed in acetone, 1.2-dimethy oxy ethane. N,N’-dimethylacetamide, dimethylsulphoxide, 1,4-dioxane, 2-ethy oxyethanol, methylethyl ketone, 2-methyl tetrahydrofuran and

[0333] tetrahydrofuran. High solubility (> 200mg / mL) was observed in N-methylpyrrolidone. Some solubility (<5 mg / mL but with partial dissolution) was also observed in acetic acid, anisole, methyl acetate and methylisobutyl ketone. In N,N’ -dimethylacetamide, dimethylsulphoxide and tetrahydrofuran, initial dissolution was observed at a higher solubility level, however recrystallization occurred during the solubility assessment. An image of the solubility samples is shown in Figure 12 and a summary of the solubility results is outlined in Table 23.

[0334] Table 23: Solvent Solubility Experimental Parameters and Results

[0335]

[0336] Page 40 of 69

[0337] SUBSTITUTE SHEET

[0338]

[0339] Temperature Cycling Screening

[0340] After determining the approximate solubility of the poorly crystalline Compound I material, temperature cycling experiments were set-up using the solubility samples. The following procedure was used for the temperature cycling experiments: The samples from the solubility assessments were set up for temperature cycling between ca. 20°C and 40°C whilst agitating. 4 hour holds at 20°C and 40°C respectively. Where slurries were observed, these were temperature cycled for 4 days whilst agitating. Where solutions or thin slurries were obtained, the solvents were allowed to evaporate or partially evaporate at ambient conditions. For solvents which were completely evaporated, the respective solvent was added back to the solids to create slurries which w ere then temperature cycled for 4 days whilst agitating. After 4 days of temperature cycling, all samples containing solids were analyzed by XRPD analysis. Any potential novel forms were dried at 40°C under vacuum for 1 day. XRPD reanalysis of potential novel forms was carried out after drying. Microscopy, TGA / DSC andJH NMR analysis was also carried out on any novel forms after drying.

[0341] The temperature cycling experimental results are summarized in Table 24 and indicated the following: 10 different crystalline solid forms were observed from the temperature cycling experiments, including Form 1, Form 2, Form 3. Form 5, Form 6, Form 7, Form 8, Form 9, Form 10, and Form 11. Form 1 was observed from multiple solvent systems (likely monohydrate). Form 2 was observed from acetone, MEK, tBME and THF (isostructural hemi-solvates). Form 3 was observed from MiBK and methyl acetate

[0342] Page 41 of 69

[0343] SUBSTITUTE SHEET

[0344] (anhydrous form). Form 5 and Form 1 was observed from ethyl acetate (unstable solvate or mixed solvate / hydrate. converts to Form 1 upon drying). Form 6 was observed from 1,4-dioxane, methanol: water (40:60% v / v) and water (likely dihydrate). Form 7 was observed from multiple solvent systems (anhydrous form). Form 8 was observed from N,N-dimethylacetamide (likely N,N- Dimethylacetamide solvate, slight changes after drying, assigned as Form 8a). Form 9 was observed from acetonitrile (likely hydrate, water is likely weakly bound as Form 9 converted to Form 7 with extensive drying). Form 10 was observed from 1 ,2-dimethoxy ethane (likely 1,2-dimethoxy ethane solvate, slight changes after drying, assigned as Form 10a). Form 11 was observed from dimethylsulfoxide (likely dimethylsulfoxide solvate). Forms 1. 2, 3, 6, 7 and 11 remained the same by XRPD analysis after drying. Form 8 and Form lO showed slight changes in the XRPD diffraction patterns after drying. Form 5 converted to Form 1 and Form 9 converted to Form 7 after extensive drying.

[0345] Table 24: Temperature Cycling Experiments - Experimental Observations, Processing and Results

[0346]

[0347] Page 42 of 69

[0348] SUBSTITUTE SHEET

[0349]

[0350] Evaporation screening

[0351] Using 24 selected solvent systems and poorly crystalline Compound I, slow evaporation experiments were set up as follows: The appropriate volume of the respective solvent was added to ca. 25 mg of poorly crystalline Compound I material, and the vials shaken and sonicated as required in order to encourage dissolution. See Table 25 for further details. The samples were then fdtered through a 0.45 pm syringe filter into separate vials. The uncapped vials containing the solutions were then placed in laboratory' ambient conditions (ca. 20°C) and allowed to evaporate. Any solids were then analyzed by XRPD analysis in order to determine the solid form. Any novel forms were analyzed XRPD, microscopy, TGA / DSC and

[0352]

[0353] NMR analysis after drying.

[0354] The evaporation experimental results are summarized in Table 3 and indicated the following: 11 different crystalline solid forms were observed from the evaporation experiments, including Form 1, Form 2, Form 4, Form 6, Form 7, Form 8, Form 9, Form 10a, Form 11, Form 13, and Form 14. Form 1 was observed from isopropyl acetate and

[0355] Page 43 of 69

[0356] SUBSTITUTE SHEET

[0357] methanol (likely monohydrate). Form 2 was observed from CPME, MEK, 2-MeTHF and THF (isostructural hemi-solvates). Form 4 was observed from 2-propanol with additional peaks also present in the diffractogram (potential hydrate or mixed solvate / hydrate). Form 6 was observed from 1,4-dioxane (likely dihydrate). Form 7 was observed from acetic acid, anisole, DCM, methyl acetate and MiBK (anhydrous form). Form 8 was observed from N,N-dimethylacetamide (likely N.N- Dimethylacetamide solvate). Form 9 was observed from acetonitrile (likely hydrate, water is likely weakly bound as Form 9 converts to Form 7 with extensive drying). Form 1 Oa was observed from 1,2-dimethoxy ethane (likely 1,2-dimethoxyethane solvate). Form 11 was observed from dimethylsulfoxide (likely dimethylsulfoxide solvate). Form 13 was observed from acetone (likely acetone solvate or mixed solvate / hydrate. Dried to Form 6 with traces of Form 2). Form 14 was observed from ethanol and 1 -propanol (unstable, dried to Form 4, likely unstable solvate or mixed solvate / hydrate.)

[0358] Table 25: Evaporation Experiments - Experimental Conditions and Results

[0359]

[0360] Page 44 of 69

[0361] SUBSTITUTE SHEET

[0362]

[0363] Cooling screening

[0364] Using 24 selected solvent systems and poorly crystalline Compound I, cooling experiments were set up as follows: The appropriate volume of the respective solvent (see Table 8) was added to ca. 25 mg of poorly cry stal 1 i ne Compound I and the samples then sonicated and heated to ca. 50°C in order to encourage dissolution. The samples were then filtered through preheated 0.45 pm syringe filters into separate vials. The vials containing the solutions were then placed at -20°C (or 20°C for solvents with a high freezing point temperature). Where solutions were present after 1-day, anti-solvent was added, and the samples placed back at the respective temperatures for a further 2 days. Any solids were then analy zed by XRPD analysis in order to determine the solid form. Any novel forms were dried at 40°C under vacuum for 1 day. XRPD reanalysis of novel forms was then carried out after drying. Microscopy, TGA / DSC and 1H NMR analysis were also carried out on any novel forms after drying. The cooling experimental results are summarized in Table 26 and indicated the following: 10 different cry stal I i ne solid forms were observed from the cooling experiments, including Form 1, Form 2, Form 7, Form 9, Form 10a, Form 13, Form 14, Form 15, and Form 16. Form 1 was observed from isopropyl acetate and ethyl acetate (likely monohydrate). Form 2 was observed from CPME, MEK and 2-MeTHF (isostructural hemi-

[0365] Page 45 of 69

[0366] SUBSTITUTE SHEET

[0367] solvates). Form 6 was observed from methanol, methanol:water(40:60%v / v), methyl acetate (likely dihydrate). Form 7 was observed from acetic acid, anisole, DCM, 1.4-di oxane, ethyl formate and MiBK (anhydrous form). Form 9 was observed from acetonitrile (likely hydrate, water is likely weakly bound as Form 9 converts to Form 7 with extensive drying). Form 10a was observed from 1,2-dimethoxy ethane (likely 1,2-dimethoxy ethane solvate).

[0368] Predominantly Form 13 was observed from acetone (likely acetone solvate or mixed solvate / hydrate. Dried to predominantly Form 6). Form 14 was observed from ethanol and 1-propanol (unstable, dried to Form 4, likely unstable solvate or mixed solvate / hydrate). Form 15 was obtained from tetrahydrofuran (tetrahydrofuran solvate). Form 16 was obtained from N,N-dimethylacetamide (dried to a material similar to Form 8, assigned Form 8b, likely N,N-dimethylacetamide solvate or potential mixed solvate / hydrate).

[0369] Table 26: Cooling Experiments - Experimental Conditions and Results

[0370]

[0371] Page 46 of 69

[0372] SUBSTITUTE SHEET

[0373]

[0374] Anti-solvent Addition at Low Temperature Experiments

[0375] Using 24 selected solvent systems and poorly crystalline Compound I, anti-solvent addition experiments were carried out as follows: the respective solvent system was added to ca. 25mg of poorly crystalline Compound I material at 5°C and the samples stirred to encourage dissolution. The samples were then filtered through 0.45 pm syringe filters. Antisolvent (either water or n-heptane, based on low solubility in these solvents) was then added dropwise to the solutions at ca. 5°C until no further precipitation was visually noted (between 10-15 mL). The samples were then placed at 5°C for ca. 2 days. Any solids were then analyzed by XRPD analysis in order to determine the solid form. Any novel forms were dried at 40°C under vacuum for 1 day. XRPD reanalysis of novel forms was then carried out after drying. Microscopy, TGA / DSC andXH NMR analysis were also carried out on any novel

[0376] Page 47 of 69

[0377] SUBSTITUTE SHEET

[0378] forms after drying. The anti-solvent addition experimental results are summarized in Table 27 and indicated the following: 7 different crystalline solid forms were observed from the antisolvent addition experiments, including Form 1, Form 2, Form 4, Form 5, Form 6, Form 7, and Form 14. Form 1 was observed from methanol / water (likely monohydrate). Form 2 was observed from acetone / n-heptane, CPME / n-heptane, 1,4- dioxane / n-heptane (with extra diffraction peaks) and 2-MeTHF / n-heptane (as a mixture with Form 7) (isostructural hemisolvates). Form 4 was obtained from 2-propanol / n-heptane and 1-propanol / n-heptane (potential mixed solvate / hydrate). Form 5 + Form 1 was observed from ethyl acetate / n-heptane (unstable solvate or mixed solvate / hydrate, converts to Form 1 upon dry ing). Form 6 was observed from Methanol: Water (40:60%v / v) / Water and Form 6 (with extra diffraction peaks) was observed from methyl acetate / n-heptane (likely dihydrate). Form 7 was observed from DCM / n-heptane, ethyl formate / n-heptane, isopropyl acetate / n-heptane, MEK / n-heptane, THF / n-heptane and 2-MeTHF / n-heptane (as a mixture with Form 2) (anhydrous form). Form 14 was observed from ethanol / n-heptane (unstable, dried to Form 4, likely unstable solvate or mixed solvate / hydrate).

[0379] Table 27: Anti-solvent Addition at Low Temperature - Experimental Conditions and Results

[0380]

[0381] Page 48 of 69

[0382] SUBSTITUTE SHEET

[0383]

[0384] Reverse Anti-solvent Addition Experiments at 40°C

[0385] Using 24 selected solvent systems and poorly crystalline Compound I, reverse antisolvent addition experiments were carried out as follows: The respective solvent system was added to ca. 25 mg of poorly crystalline Compound I material, and the samples then sonicated and heated to ca. 40°C in order to encourage dissolution. The samples were then filtered through preheated 0.45 pm syringe filters. The solutions were then added to vials containing 15 mL of anti-solvent heated to 40°C. A variety of different anti-solvents were assessed including water, n-heptane, DIPE, tBME, / c / 7-butanol and acetonitrile. Water and n-heptane were

[0386] Page 49 of 69

[0387] SUBSTITUTE SHEET

[0388] observed to be more effective anti-solvents. Due to gel-like suspensions initially observed, the samples were agitated at 40 °C for 1 day and any solids were then analyzed by XRPD analysis in order to determine the solid form. Any novel forms were dried at 40°C under vacuum for 1 day. XRPD reanalysis of novel forms was then carried out after drying. Microscopy, TGA / DSC and 'H NMR analysis were also carried out on any novel forms after drying. The reverse anti-solvent addition experimental results are summarized in Table 28. 8 different crystalline solid forms were observed from the reverse anti-solvent addition experiments, including Form 1, Form 2, Form 5, Form 6, Form 7, Form 8, Form 9, and Form 10. Form 1 was observed from acetic acid / water (likely monohydrate). Form 2 was observed from acetone / DIPE, anisole / tBME, CPME / DIPE. ethanol / tBME, and 2-MeTHF / n-heptane (as a mixture with Form 7) (isostructural hemi-solvates). Form 5 + Form 1 was observed from ethyl acetate / DIPE (unstable solvate or mixed solvate / hydrate, converts to Form 1 upon drying). Form 6 was observed from methanol / water, 1-propanol / water, 2-propanol / water and methyl acetate / n-heptane (with extra diffraction peaks) (likely dihydrate). Form 7 was observed from acetic acid / water, DCM / DIPE, MEK / n-heptane, MiBK / n-heptane, 2- MeTHF / n-heptane (as a mixture with Form 2) and 1,2- dimethoxy ethane / DIPE (as a mixture with Form 10) (anhydrous form).

[0389] Table 28: Reverse Anti-solvent Addition at 40°C - Experimental Conditions and Results

[0390]

[0391] Page 50 of 69

[0392] SUBSTITUTE SHEET

[0393]

[0394] In summan', the polymorph screening of Compound I was carried out using poorly crystalline input material. Overall, 16 different solid forms were observed during the polymorph screen including anhydrous forms, hydrates and solvates.

[0395] Desolvation of solvates and hydrates

[0396] During the primary polymorph screening studies, different solvates or hydrates were observed. Desolvation / dehydration experiments were therefore carried out to determine the anhydrous forms obtained by heating the solvates / hydrates beyond their desolvation / dehydration temperatures. The solvates / hydrates were heated to appropriate

[0397] Page 51 of 69

[0398] SUBSTITUTE SHEET

[0399] temperatures to allow for desolvation / dehydration to occur. XRPD analysis was then carried out after the samples had cooled back to room temperature to determine the form after desolvation / dehydration. See Table 29 for a summary of the experimental conditions and results. The desolvation / dehydration experiments resulted in two novel forms being located including Form 17 and Form 18.

[0400] Table 29: Desolvation / Dehydration Experimental Conditions and Results

[0401]

[0402] Competitive slurry experiments (for anhydrous and hydrates)

[0403] Competitive slurry experiments were carried out to determine the thermodynamically most stable form out of the anhydrous forms (Form 3, Form 7, Form 12, Form 17 and Form 18). Four solvent systems were selected, including three solvents that had predominantly resulted in anhydrous forms during the polymorph screening studies and one solvent (2-MeTHF) that had favored Form 2 or mixtures with Form 2 during the primary polymorph screen. The following general procedure was used for the set-up of the competitive slurry experiments: Saturated solutions were initially prepared at 20 and 50°C in acetic acid, ethyl

[0404] Page 52 of 69

[0405] SUBSTITUTE SHEET

[0406] formate, methylisobutyl ketone and 2-methyl tetrahydrofuran using Form 7 material by creating slurries of Form 7 in the respective solvent systems. The solutions were then filtered at the respective temperatures for use during the competitive slurry experiments. Mixtures of Form 2, Form 3, Form 7, Form 12, Form 17, and Form 18 were prepared by adding ca. 5 mg of each form to each of 8 vials, ca. 1 mL of the saturated solutions was then added to the appropriate vials to create slurries of the mixture of forms at both 20 and 50°C. The slurries were stirred at the respective temperatures and were analyzed periodically by XRPD until complete conversion to a single form was observed. Analysis timepoints included 5, 9, 12 and 13 days. After 13 days, all slurries were converted to a single form showing either Form 2 or Form 3.

[0407] The results indicate that Form 3 is the thermodynamically most stable anhydrous form under the conditions assessed. The conversions also indicated that in specific solvent systems, Form 2 was favored. Based on characterization of Form 2, it has been confirmed to be an isostructural hemi-solvate which can be obtained from multiple solvent systems. The hemisolvate was obtained from ethyl formate and 2-methyl THF.

[0408] Hydration assessment

[0409] Further hydration screening studies focused on assessing the propensity of Compound I for forming different hydrates, and the conditions under which hydrate formation may occur. The hydration studies included the use of two solvent systems at three different water activities and two temperatures.

[0410] Hydration experiments were set up using a mixture of Form 1, Form 4, Form 6 and Form 9 as input material. The following general procedure was used: Saturated solutions were initially prepared at 20 and 50°C in methanol, methanol: water (95:5% v / v), methanol: water (50:50% v / v), 2-Propanol, 2-Propanol: water (95:5% v / v) and methanol: water (50:50% v / v) using Fonn 1 by creating slurries of Form 1 in the respective solvent systems. The solutions were then filtered at the respective temperatures for use during the hydration experiments. Mixtures of Form 1, Form 4, Form 6 and Form 9 were prepared by adding ca.

[0411] 5mg of each form to each of 12 vials. Approximately, 1 mL of the saturated solutions was then added to the appropriate vials to create slurries of the mixture of forms at both 20°C and 50°C. The slurries were stirred at the respective temperatures and analyzed after 4 days. XRPD analysis was carried out on the hydration experiments after 4 days. Form 1 was

[0412] Page 53 of 69

[0413] SUBSTITUTE SHEET

[0414] observed for all methanol / water systems. Form 4, a mixed hydrate / solvate was observed in 2-propanol and Form 6, a likely dihydrate was observed in 2-propanol / water at high water activity.

[0415] Table 30: Hydration Screening Experimental Conditions and Results using a Mixture of Input Forms

[0416]

[0417] Assessment of exemplary forms

[0418] The solubility and 2-week stability of Form 1, Form 3 and Form 2 were summarized in Table 31.

[0419] Page 54 of 69

[0420] SUBSTITUTE SHEET

[0421] Table 31: 2-Week Stability and pH Solubility Assessments for Form 1, Form 3, and Form 2

[0422]

[0423] *LOQ (Limit of Quantification) = 0.0005 mg / mL

[0424] The 'H NMR data carried out for various samples of Form 2 during the polymorph screening studies is summarized below. All samples have shown between 0.4 and 0.5 mole equivalents of solvent present after dr ing. Single cry stal XRD analysis confirmed that Form 2 is an isostructural hemi-solvate. Single crystal XRD also indicated that Compound I forms isostructural hemisolvates, where there are two formula units of the Compound I target molecule, and one molecule of solvent in the asymmetric unit.

[0425] Page 55 of 69

[0426] SUBSTITUTE SHEET

[0427]

[0428] Biological results of Compound I

[0429] Fluorogenic peptide detection of Calcineurin phosphatase activity of Compound I

[0430] Calcineurin dephosphorylates the fluorogenic peptide AQT0670 (AssayQuant) in a time-dependent process. Calcineurin is a heterodimeric enzyme of Calcineurin A and B subunits. Both the alpha(a) and beta(b) isoforms of Calcineurin A were tested in the following assay. By combining calcineurin, calmodulin, and AQT0670, the fluorescent signal will decrease over time and the measured slope can be determined and normalized for activity. Specifically, test and control compounds were 2X serially diluted in a 12-point dose curve in the 96-well compound plates (top final concentrations vary ing from 1 to 80 pM), and 1 pL was added in duplicate side by side into the black polystyrene 384 well plates with a nonbinding surface (Coming, cat# 3575). 2X Stocks of enzyme, substrate / calmodulin and substrate were prepared in assay buffer (25 mM HEPES, pH 7.5, 100 mM NaCl, 1.5 mM CaCh, 6 mM MgCk, 0.01% Tween-20, 1 mM TCEP) such that the final concentrations in the assay were as follows in 25 pL reaction volume:

[0431]

[0432] Page 56 of 69

[0433] SUBSTITUTE SHEET

[0434] First. 2X enzyme solutions were aliquoted to the corresponding wells on the assay plate. Assays for the a isoform had 2X enzyme solutions in all wells except for the 100% inhibition wells that only had buffer added, and the assay was begun with the addition of 2X substrate / calmodulin to all wells. For f> isoform assays, 2X enzyme solutions were added to all wells, and the assay was begun with addition of 2X substrate / calmodulin to all wells other than the 100% inhibition wells where only 2X substrate was added.

[0435] After reaction initiation, the fluorescence intensity is measured continuously for 1.5 hours exciting at 360 nm and monitoring emission at 485 nm on a BMG CLARIOstar microplate reader at room temperature. Slope values (change in fluorescence intensity / min) were determined over the linear portion of curve for each well using the kinetic calculation function of the MARS data analysis software (BMG LabTech) for all samples. The inhibitor dose response curves were analyzed using a normalized IC50 regression curve fitting model (4 parameters) with control-based normalization. The IC50 of Compound I was determined to be 0.015 mM.

[0436] NF T-Luciferase Reporter Assay

[0437] The following protocol is a luciferase-based reporter assay to measure inhibition of nuclear factor of activated T-cells (NFAT) in cellular lysates mediated by calcineurin inhibitors. Jurkat T cells, engineered with a luciferase reporter controlled by NFAT-response elements were used in this assay. When stimulated with calcium ionophores or T-cell receptor (TCR) stimulants, Calcineurin dephosphorylates NFAT which then translocates to the nucleus. Activated nuclear NFAT binds the NFAT-response elements and induces transcription of the luciferase signal. Percent inhibition in this assay was measured by the reduction of the luciferase signal.

[0438] Cell line

[0439] NFAT Reporter (Luc)-Jurkat Recombinant Cell Line (BPS BioScience, 60621).

[0440] Page 57 of 69

[0441] SUBSTITUTE SHEET

[0442] Buffer Components

[0443] RPMI Cell culture media= RPMI-1620 (ATCC-30-2001) + 10% FBS (ATCC 30-2020) + 2mM L-Glutamine (ATCC 30-2214); (RPMI = Roswell Park Memorial Institute, FBS = fetal bovine serum).

[0444] G418 = Geneticin Selective Antibiotic (G418 Sulfate) (1 mg / mL final concentration) (Thermo Fisher, 10131035).

[0445] Assay Reagents

[0446] DMSO (Hybri-max (Sigma D2650, 5 x 5mL ampules), ONE-Step luciferase assay system (BPS, 60690), Phorbol 12-myristate 13-acetate (PMA, Sigma, P8139), lonomycin (Sigma, 11957).

[0447] Procedure

[0448] NF AT Reporter (Luc) Jurkat Recombinant Cell Line stocks were maintained in RPMI media containing Img / mL G418. 24-48h prior to assay, cells were washed and resuspended in RPMI without G418. Cells were plated into an assay plate at 0.5-0.7xl06cells / well in 40 pL RPMI media in a 96 well plate on the day of assay.

[0449] Test compounds were reconstitued in DMSO and serially diluted to desired concentrations (3-fold, 9-point dose response), and 5 pL of each was added to the cells in the assay plate. PMA and lonomycin were added to cells at afinal concentration of 18.5ng / mL and 750 ng / mL, respectively. Treated cells were incubated at 37 °C, 5% CO2 for 4h.

[0450] Upon completion of incubation, the assay plate was equilibrated to room temperature for approximately 20 min. ONE-Step Luciferase Assay system was added (1:1 by volume) to each well, and the plate was incubated on plate shaker for 10 min at room temperature. The sample luminescence was measured using a CLARIOstar Plate Reader.

[0451] Data Analysis

[0452] Data analysis were normalized by calculating the percent response / inhibition for each of the sample values with 100% inhibition defined as the Cyclosporin treated control and 0% inhibition as the DMSO vehicle control. The data points for each compound are fit to a 4PL dose-response curve. The calculated IC50 of Compound I was 0.0012 mM.

[0453] Page 58 of 69

[0454] SUBSTITUTE SHEET

[0455] Rat Whole Blood IL-2 Secretion Assay

[0456] The following protocol measures the secreted protein levels of IL-2 in ex vivo mitogen stimulated rat whole blood and response / inhibition assessed with calcineurin inhibitor treatment. Inhibition of calcineurin impedes dephosphorylation of its substrate, NF AT preventing nuclear localization thereby blocking expression of cytokine genes like IL-2, necessary’ for T-cell activation. Percent inhibition of IL-2 was quantified by the reduction of the IL-2 levels using ELISA based methods on treated whole blood supernatants.

[0457] Primary cells:

[0458] Rat whole blood, ~7-8 week old male Wistar Han. BioIVT.

[0459] Cell culture Reagents:

[0460] RPMI 1640; high glucose, ATCC Catalog# 30-2001, lx DPBS, Coming Catalog# 21-031-CV, DMSO: Hybri-max, Sigma D2650, 5 x 5mL ampules.

[0461] Other reagents:

[0462] Concanavalin A (ConA), MP Catalog# 150710, Rat IL-2 Quantikine ELISA, R&D Biosciences, Catalog #R2000.

[0463] Procedure

[0464] Whole blood volume of 190ul were dispensed into each well of 96 well plate and stimulated ex vivo with Concanavalin A (20pg / ml) with the addition of vehicle (DMSO) or test compounds. Test compounds were reconstituted in DMSO and serially diluted (4-fold, 12-point dose response), to desired concentrations and incubated at 37 °C, 5%

[0465] CO2. Supernatants were harvested after 24 hours following centrifugation for 15min at 2200Xg at RT. Supernatants were diluted and tested for IL-2 protein levels following manufacturer’s instructions (Rat IL-2 Quantikine ELISA, R&D Biosciences, Catalog #R2000). Samples were measured at 450 & 570nm using the CLARIOstar Plate Reader within 30 min of addition of stop solution. Subtract 570 nm reading from 450 nm as the wavelength corrected values to use for analysis.

[0466] Page 59 of 69

[0467] SUBSTITUTE SHEET

[0468] Data Analysis

[0469] The data were normalized by calculating percent inhibition for Compound I with 100% inhibition defined as the unstimulated plate control and 0% inhibition as stimulated plate control. The data points for each compound are fit to a 4PL dose-response curve. The calculated ICso data was 0.056 mM.

[0470] The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.

[0471] While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. It will also be understood that none of the embodiments described herein are mutually exclusive and may be combined in various ways without departing from the scope of the invention encompassed by the appended claims.

[0472] Page 59a of 69

[0473] SUBSTITUTE SHEET

Claims

CLAIMS1. A crystalline form of Compound I, having the structure of formula (I):formula (I); wherein the cry stalline form is of a free acid, a hydrate, a solvate, or any combination thereof.

2. The crystalline form of claim 1, wherein the crystalline form is of a free acid.

3. The crystalline form of claim 2, wherein the crystalline form of the free acid is selected from:Form 3, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.7, 10.2, 11.9, 14.8, 15.4, 20.5, 22.7, and / or 24.0°0 using CuKa radiation;Form 7, characterized by having one or more XRPD peaks at approximately 6.8, 15.4, 23.1, 25.9, and / or 29.4°9 using CuK a radiation;Form 12, characterized by having one or more XRPD peaks at approximately 3.5, 7.1,14.8, 15.5, and / or 22.7°0 using CuKa radiation;Form 17, characterized by having one or more XRPD peaks at approximately 6.6,14.9, 15.7, 20.0, and / or 23.4°0 using CuK radiation; andForm 18, characterized by having one or more XRPD peaks at approximately 13.2, 14.4, 15.0, 16.2, and / or 22.4°0 using CuKa radiation.

4. The crystalline form of claim 3, wherein the crystalline form of the free acid is Form 3, characterized by having three or more X-ray powder diffraction (XRPD) peaks atapproximately 6.7, 10.2, 11.9, 14.8, 15.4, 20.5, 22.7, and / or 24.0°9 using CuK a radiation.

5. The crystalline form of claim 1, wherein the crystalline form is of a hydrate.

6. The cry stalline form of claim 5, wherein the crystalline form is of a mono-hydrate.

7. The crystalline form of claim 5, wherein the crystalline form is selected fromForm 1, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.7, 10.2, 11.9, 14.8, 15.4, 20.5, 22.7, and / or 24.0°0 using CuK a radiation;Form 4, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 14.7, 15.3, 22.5, 24.6, and / or 26.0°0 using CuK a radiation;Form 5, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.0, 15.0, 21.2, 22.8, and / or 24.3°0 using CuK a radiation;Form 6, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.

8. 9.7, 13.2, 15.0, 19.

5. 22.

6. 23.6, 26.2, and / or 3O.3°0 using CuK a radiation;Form 9, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.4, 14.9, 19.9, 21.9, and / or 23.3°0 using CuK a radiation;Form 13, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 13.9, 19.9, 22.5, 23.6, and / or 25.O°0 using CuK a radiation; andForm 19, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.7, 14.9, 20.

5. 23.9, and / or 25.8°0 using CuK a radiation.

8. The crystalline form of claim 7, wherein the crystalline form is Form 1, characterized by having three or more XRPD peaks at approximately 6.7, 10.2, 11.9, 14.8, 15.4, 20.5, 22.7, and / or 24.O°0 using CuK a radiation; Form 6, characterized by having three or more XRPD peaks at approximately 6.8, 9.7, 13.2, 15.0, 19.5, 22.6, 23.6, 26.2, and / or 3O.3°0 using CuK a radiation; or Form 19, characterized by having threeor more XRPD peaks at approximately 6.7, 14.9, 20.5, 23.9, and / or 25.8°9 using CuK a radiation.

9. The crystalline form of claim 1, wherein the crystalline form is of a solvate.

10. The crystalline form of claim 9, wherein the ciystalline form is of a hemi-solvate.

11. The crystalline form of claim 9, wherein the crystalline form is of DMA solvate, 1,2- dimethoxy ethane solvate, DMSO solvate, THF solvate, DCM solvate, acetone solvate. MEK solvate, or methyl acetate solvate.

12. The cry stalline form of claim 11, wherein the ciy stalline form is of THF hemi-solvate, DCM hemi-solvate, acetone hemi-solvate, MEK hemi-solvate, methyl THF hemi- solvate or methyl acetate hemi-solvate.

13. The crystalline form of any one of claims 9-12, wherein the crystalline form is selected from:Form 2, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 7.5, 8.8, 11.9, 14.1, 15.1, 15.8, 17.8, 20.3, and / or 24.3°0 using CuK a radiation;Form 8, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 7.9, 14.8, 15.3, 19.8, and / or 22.1°0 using CuK a radiation;Form 8a, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 7.9, 15.0, 15.

8. 22.6, and / or 31.1°0 using CuK a radiation; Form 10, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 7.2, 20.4, 22.7, 24.2, and / or 29.4°0 using CuK a radiation;Form 11, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 13.7, 16.0, 24.9, 30.0, and / or 38.4°0 using CuK a radiation; Form 14, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 6.6, 20.1, 23.

5. 26.0, and / or 29.2°0 using CuK a radiation;Form 15, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 9.1, 13.0, 15.

3. 17.

7. 21.

4. and / or 22.5°0 using CuK a radiation; andForm 16, characterized by having one or more X-ray powder diffraction (XRPD) peaks at approximately 8.2, 14.7, 15.9, 19.7, and / or 23.2°0 using CuK a radiation.

14. The cry stalline form of claim 13, wherein the crystalline form is Form 2, characterized by having three or more XRPD peaks at approximately 7.5, 8.8, 11.9,14.1, 15.1, 15.8, 17.8, 20.3, and / or 24.3 °0 using CuK a radiation;Form 10, characterized by having three or more XRPD peaks at approximately 7.2, 20.4, 22.7, 24.2, and / or 29.4°0 using CuK a radiation; orForm 11, characterized by having three or more XRPD peaks at approximately 13.7, 16.0, 24.9, 30.0, and / or 38.4°0 using CuK a radiation.

15. The crystalline form of claim 14, wherein the crystalline form is Form 2, characterized by having four or more XRPD peaks at approximately 7.5, 8.8, 11.9,14.1, 15.1, 15.8, 17.8, 20.3, and / or 24.3°0 using CuK a radiation.

16. The crystalline form of claim 1, wherein the crystalline form is selected from:Form 1, characterized by having one or more XRPD peaks at approximately 6.7, 10.2, 11.9, 14.8, 15.4, 20.5, 22.7, and / or 24.O°0 using CuK a radiation;Form 2, characterized by having one or more XRPD peaks at approximately 7.5, 8.8.11.9, 14.1, 15.1, 15.8, 17.8, 20.3, and / or 24.3°0 using CuK a radiation;Form 3, characterized by having one or more XRPD peaks at approximately 6.9, 14.8, 15.0, 22.6, 23.2, and / or 25.O°0 using CuK a radiation;Form 4, characterized by having one or more XRPD peaks at approximately 14.7, 15.3, 22.5, 24.6, and / or 26.O°0 using CuK a radiation;Form 5, characterized by having one or more XRPD peaks at approximately 6.0, 15.0,21.2, 22.8, and / or 24.3°0 using CuK a radiation;Form 6, characterized by having one or more XRPD peaks at approximately 6.8, 9.7,13.2, 15.0, 19.5, 22.6, 23.6, 26.2, and / or 3O.3°0 using CuK a radiation;Form 7, characterized by having one or more XRPD peaks at approximately 6.8, 15.4,23.1, 25.9, and / or 29.4°0 using CuK a radiation;Form 8, characterized by having one or more XRPD peaks at approximately 7.9, 14.8,15.3, 19.8, and / or 22.1 °0 using CuK a radiation;Form 8a, characterized by having one or more XRPD peaks at approximately 7.9, 15.0, 15.8, 22.6, and / or 31.1°0 using CuK a radiation;Form 8b, characterized by having one or more XRPD peaks at approximately 13.1,15.3, 22.3, 23.0, and / or 31.6°0 using CuK a radiation;Form 9, characterized by having one or more XRPD peaks at approximately 6.4, 14.9,19.9, 21.9, and / or 23.3°0 using CuK a radiation;Form 10. characterized by having one or more XRPD peaks at approximately 7.2,20.4, 22.7, 24.2, and / or 29.4°0 using CuK a radiation;Form 10a, characterized by having one or more XRPD peaks at approximately 7.3, 14.8, 17.8, 22.8, and / or 29.5°0 using CuK a radiation;Form 11, characterized by having one or more XRPD peaks at approximately 13.7.16.0, 24.9, 30.0, and / or 38.4°0 using CuK a radiation;Form 12, characterized by having one or more XRPD peaks at approximately 3.5, 7.1,14.8, 15.5, and / or 22.7°0 using CuK a radiation;Form 13, characterized by having one or more XRPD peaks at approximately 13.9.19.9, 22.5, 23.6, and / or 25.O°0 using CuK a radiation;Form 14, characterized by having one or more XRPD peaks at approximately 6.6,20.1, 23.5, 26.0, and / or 29.2°0 using CuK a radiation;Form 15, characterized by having one or more XRPD peaks at approximately 9.1, 13.0, 15.3, 17.7, 21.4, and / or 22.5°0 using CuK a radiation;Form 16, characterized by having one or more XRPD peaks at approximately 8.2, 14.7, 15.9, 19.7, and / or 23.2°0 using CuK a radiation;Form 17, characterized by having one or more XRPD peaks at approximately 6.6,14.9, 15.7, 20.0, and / or 23.4°0 using CuK a radiation;Form 18, characterized by having one or more XRPD peaks at approximately 13.2,14.4, 15.0, 16.2, and / or 22.4°0 using CuK a radiation; andForm 19, characterized by having one or more XRPD peaks at approximately 6.7, 14.9, 20.5, 23.9, and / or 25.8°0 using CuK a radiation.

17. The crystalline form of claim 16, wherein the crystalline form is Form 1, characterized by having four or more XRPD peaks at approximately 6.7, 10.2, 11.9,14.8, 15.4, 20.5, 22.7, and / or 24.0°0 using CuK a radiation; Form 2, characterized by having four or more XRPD peaks at approximately 7.5, 8.8, 11.9, 14.1, 15.1, 15.8,17.8, 20.3, and / or 24.3°0 using CuK a radiation; or Form 3, characterized by having four or more XRPD peaks at approximately 6.9, 14.8, 15.0, 22.6, 23.2, and / or 25.O°0 using CuK a radiation.

18. A dosage form comprising a therapeutically effective amount of Compound I in the crystalline form of any one of claims 1-17.

19. The dosage form of claim 18, wherein the dosage form is for injection administration.

20. A method for treating an inflammatory-related disease or disorder in a subject in need thereof, wherein the method comprises administering to the subject the dosage form of claim 18.

21. The method of claim 20, wherein the inflammatory-related disease or disorder is a systemic inflammatory-related disease or disorder.

22. The method of claim 21, wherein the inflammatory-related disease or disorder is a pulmonary condition.

23. The method of claim 22, wherein the compound is administered to the subject via inhalation.

24. The method of claim 20, wherein the inflammatory-related disease or disorder is selected from the group consisting of allergic rhinitis, asthma, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, emphysema, bronchitis, mucus hypersecretion, silicosis, SARS infection, and respiratory tract inflammation.

25. The method of claim 20, wherein the inflammatory-related disease or disorder is a skin condition.

26. The method of claim 20, wherein the inflammatory-related disease or disorder is selected from the group consisting of psoriasis, dermatitis, eczema, and hives.

27. The method of claim 20, wherein the inflammatory-related disease or disorder is psoriasis.

28. The method of claim 27, wherein psoriasis is selected from the group consisting of plaque psoriasis, flexural psoriasis (inverse psoriasis), guttate psoriasis, pustular psoriasis, nail psoriasis, psoriatic arthritis, and erythrodermic psoriasis.

29. The method of claim 20, wherein the inflammatory-related disease or disorder is dermatitis.

30. The method of claim 29, wherein the dermatitis is selected from the group consisting of contact dermatitis, atopic dermatitis, nummular dermatitis, seborrheic dermatitis, and stasis dermatitis.

31. The method of claim 20, wherein the inflammatory-related disease or disorder is an ocular disorder or disease.

32. The method of claim 31, wherein the ocular disorder or disease is selected from the group consisting of dry eye syndrome (DES), Sjogren's syndrome, uveitis, conjunctivitis (pink eye), keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC). atopic keratoconjunctivitis (AKC), autoimmune disorders of the ocular surface, including cicatrizing conjunctivitis, blepharitis, and scleritis.

33. A method of inhibiting calcineurin, wherein the method comprises administering to the subject the dosage form of claim 18.

34. A method of preventing organ transplant rejection in a subject in need thereof, wherein the method comprises administering to the subject the dosage form of claim 18.

35. A method of treating fungal infection in a subject in need thereof, comprising administering to the subject the dosage form of claim 18.

36. A method of protecting a kidney by reducing immunosuppression-induced nephrotoxicity in a subject in need, wherein the method comprises administering to the subject the dosage form of claim 18.

37. A method of treating a condition or disorder associated with abnormal Calcineurin activity in a subject in need, wherein the method comprises administering to the subject the dosage form of claim 18.

38. A method of treating inflammatory bowel disease or acute severe ulcerative colitis in a subject in need thereof, comprising administering to the subject the dosage form of claim 18.

39. The method of claim 20, wherein the inflammatory-related disease or disorder is selected from the group consisting of focal segmental glomerulosclerosis, lupus nephritis, IgA nephropathy or myasthenia gravis.

40. The method of claim 20, wherein the inflammatory-related disease or disorder is selected from the group consisting of allergic conjunctivitis, aplastic anemia, atopic dermatitis, Behcet’s disease, dry eye / keratoconjunctivitis, graft- versus-host disease, interstitial pneumonia, Kawasaki disease, keratitis, lupus nephritis, nephrotic syndrome, psoriasis, rheumatoid arthritis, transplant rejection, ulcerative colitis, uveitis, autoimmune hepatitis, bullous pemphigoid, Crohn’s disease, FS glomerulosclerosis, Goodpasture’s disease, Graves disease, IgA nephropathy, idiopathic inflammatory myositis, membranous glomerulonephritis, minimal change disease, multiple sclerosis, myasthenia gravis, pemphigoid vulgaris, Sjogren's syndrome, systemic sclerosis, and type 1 diabetes.